Display options
Cite
Zyczynski LE, McHugh JB, Gribbin TE, et al. Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. Case Rep Oncol Med. 2015;2015:107479doi: 10.1155/2015/107479.
Zyczynski, L. E., McHugh, J. B., Gribbin, T. E., & Schuetze, S. M. (2015). Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. Case reports in oncological medicine, 2015107479. https://doi.org/10.1155/2015/107479
Zyczynski, Laura E, et al. "Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy." Case reports in oncological medicine vol. 2015 (2015): 107479. doi: https://doi.org/10.1155/2015/107479
Zyczynski LE, McHugh JB, Gribbin TE, Schuetze SM. Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. Case Rep Oncol Med. 2015;2015:107479. doi: 10.1155/2015/107479. Epub 2015 Jul 22. PMID: 26266067; PMCID: PMC4525456.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol Med. 2015;2015:107479. doi: 10.1155/2015/107479. Epub 2015 Jul 22.

Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy.

Case reports in oncological medicine

Laura E Zyczynski, Jonathan B McHugh, Thomas E Gribbin, Scott M Schuetze

Affiliations

  1. Department of Internal Medicine, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
  2. Department of Pathology, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
  3. Mercy Health Lacks Cancer Center, 250 Cherry Street SE, Grand Rapids, MI 489503, USA.

PMID: 26266067 PMCID: PMC4525456 DOI: 10.1155/2015/107479

Abstract

A 69-year-old woman was diagnosed with alveolar rhabdomyosarcoma (ARMS) of the nasopharynx. She has a history of catastrophic thromboembolic event in the abdomen that caused short-gut syndrome and dependence on total parenteral nutrition (TPN) twelve hours per day. She was treated for short-gut syndrome with teduglutide, a glucagon-like peptide-2 (GLP-2) analog, which led to reduction of TPN requirements. However, a few months later, she developed metastatic alveolar rhabdomyosarcoma. Though a causative relationship is unlikely between the peptide and ARMS due to the brief time course between teduglutide therapy and sarcoma diagnosis, neoplastic growth may have been accelerated by the GLP-2 analog, causing release of IGF-1. The transmembrane receptor for IGF-1 is frequently overexpressed in ARMS and is implicated in cell proliferation and metastatic behavior. This case describes a rare incidence of metastatic alveolar rhabdomyosarcoma in a sexagenarian and possibly the first case reported associated with the use of teduglutide. Teduglutide was discontinued due to a potential theoretical risk of acceleration of sarcoma growth, and the patient's rhabdomyosarcoma is in remission following sarcoma chemotherapy.

References

  1. Adolesc Health Med Ther. 2014 Jun 17;5:115-25 - PubMed
  2. Gastroenterology. 2012 Dec;143(6):1473-1481.e3 - PubMed
  3. Cancer. 2003 Aug 1;98(3):571-80 - PubMed
  4. Sarcoma. 2011;2011:209736 - PubMed
  5. J Clin Invest. 1994 Sep;94(3):1235-42 - PubMed
  6. J Clin Oncol. 2011 Apr 1;29(10):1304-11 - PubMed
  7. Gastroenterology. 2011 Dec;141(6):2166-2175.e7 - PubMed
  8. Histopathology. 2014 Jan;64(1):68-87 - PubMed
  9. Clin Transl Oncol. 2007 Jul;9(7):415-9 - PubMed
  10. Mol Cell Endocrinol. 2012 Nov 25;364(1-2):46-53 - PubMed
  11. Cancer Res. 1994 Nov 1;54(21):5531-4 - PubMed
  12. Gastroenterology. 2006 Aug;131(2):589-605 - PubMed
  13. Int J Oncol. 2007 Jul;31(1):41-7 - PubMed
  14. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  15. J Clin Oncol. 2009 Jul 10;27(20):3391-7 - PubMed
  16. Gut. 2011 Jul;60(7):902-14 - PubMed
  17. Int J Oncol. 2005 Oct;27(4):1087-96 - PubMed
  18. Drugs. 2013 Jun;73(9):935-47 - PubMed

Publication Types